egf-r

EGF-R (661-681) T669 Peptide, a substrate of MAPK, facilitates the measurement of MAPK catalytic activity [1].

Nelipepimut-S, as an immunogenic peptide from the HER2 protein, is highly expressed in breast cancer.

EGFR Protein Tyrosine Kinase Substrate is an EGFR protein tyrosine kinase substrate.

ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, shows significant potential for cancer research applications [1].

Oligopeptide-41, a bioactive peptide, is recognized for its hair growth-promoting properties and is reported as an ingredient in cosmetics [1].

OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2 and holds potential for research on kidney fibrosis and chronic kidney disease [1].

Epidermal Growth Factor binds to epidermal growth factor receptor (EGFR) and stimulates cell growth and proliferation. It is approved for the treatment of diabetic foot ulcers.

PACAP-38 (31-38), human, mouse, rat (TFA), exhibits potent, efficacious, and sustained stimulatory effects on sympathetic neurons.

Affibody (affibody) ligands that are specific for the extracellular domain of human epidermal growth factor receptor 2 (HER2/neu) have been selected by phage display technology from a combinatorial protein library based on the 58 amino acid residue staphy

PACAP-38 (31-38), [human, mouse, rat], exhibits potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production.

Candidalysin is a cytolytic peptide toxin initially isolated from *Candida albicans*, exhibiting both toxic and non-toxic properties. It activates epithelial cell signaling pathways by interacting with the epithelial growth factor receptor (EGFR) on host cells, leading to the activation of matrix metalloproteinases (MMP) and calcium ion influx, which results in inflammatory responses and immune cell recruitment. Additionally, Candidalysin exhibits cytotoxicity by causing membrane damage to host cells.

Cyclic(YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anticancer properties. In aqueous solution, Cyclic(YCDGFYACYMDV) self-assembles into nanoparticles that target HER2 on cancer cells, converting into nanofibrils. This process disrupts HER2 dimerization and subsequent downstream signaling, leading to apoptosis (Apoptosis) of cancer cells. Its inhibitory effect on HER2-positive breast cancer has been demonstrated as effective in mouse xenograft models.

HER2-targeted peptide H6F is a molecule designed to bind to HER2 and target breast cancer cells, characterized by the amino acid sequence YLFFVFER. It can conjugate with the bifunctional chelator hydrazinonicotinamide (HYNIC) for binding with 99mTc for radiolabeling purposes. Single-photon emission computed tomography (SPECT) imaging demonstrates that the radiolabeled HER2-targeted peptide H6F specifically accumulates in HER2-positive MDA-MB-453 tumor-bearing mouse models. This peptide is useful for studies in tumor molecular imaging.

LARLLT TFA is an EGFR-binding peptide. LARLLT shows research potential for cancers with EGFR overexpression, such as lung cancer, ovarian cancer, and colorectal cancer.

LARLLT (D4) is an EGFR-binding peptide. It shows potential for research in cancers with EGFR overexpression, such as lung, ovarian, and colorectal cancers.

[pTyr5] EGFR (988-993) TFA, derived from the Tyr992 autophosphorylation site of the epidermal growth factor receptor (EGFR 988-993), often complexes with catalytically inactive protein-tyrosine phosphate 1B (PTP1B) [1].

EGFR peptide, a PKC peptide substrate, mirrors an amino acid sequence from EGFR's intracellular region and serves to gauge PKC activity in primary bovine retinal endothelial cells. At a concentration of 50 µM, unlike its myristoylated counterpart, EGFR peptide does not inhibit PKC activity.

EGFRPeptide is a substrate peptide for PKC. It can be used for assaying PKC activity.

Oglufanide (H-Glu-Trp-OH) is a naturally occurring thymic immunomodulator that inhibits vascular endothelial growth factor (VEGF).

Epidermal Growth Factor Receptor Peptide Acetate exists on the cell surface and is activated by the binding of its specific ligands.EGFR belongs to the ErbB family of receptor tyrosine kinases (RTK).

Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, exhibits potent antiproliferative activity, induces autophagosome accumulation via an mTOR-independent mechanism, and triggers apoptosis. Furthermore, it inhibits VEGFA/VEGFR2 expression, effectively suppressing tumor growth in glioblastoma xenografts [1] [2].

Arginyl-Glutamine (Arg-Gln) is a dipeptide nutritional supplement that protects against hyperoxic lung injury in neonatal mice, reducing VEGF levels and inhibiting retinal neovascularization in a mouse model of oxygen-induced retinopathy, also alleviating lung injury in neonatal mice.

Protein LMWP, a cell-penetrating peptide, exhibits inhibitory activity against vascular endothelial growth factor (VEGF), and is utilized in cancer research for its potential to impede tumor proliferation [1].

PKCε (85-92) (ψεRACK) is a peptide and selective PKCε activator that does not affect the activity of other PKC isozymes.PKCε (85-92) induces a pro-angiogenic response in endothelial cells, promotes FGF-2 cytosolization, and regulates VEGF activity.